Pharmaceutical formulation and process
AssigneeNeXstar Pharmaceuticals, Inc.
InventorsJill P. Adler-Moore, William A. Ernst
Life of this patent
Estimating the term…
Abstract
A process for preparing a liposomal cyclosporin therapeutic formulation, which comprises dissolving a combination of a neutral and negatively charged phospholipid and a cyclosporin in an organic solvent; drying the solution to form a solid phase, and hydrating the solid phase in an aqueous solution having a pH ranging from 7.5 to 9.5.
Claims21
Liposomes consisting essentially of (i) a phosphatidylcholine having lipid portions principally composed of straight 16 or 18 carbon fatty acid chains, (ii) a negatively charged lipid selected from the group consisting of dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dilaurylphosphatidylglycerol, and dimyristoylphosphatidic acid, (iii) cholesterol, and (iv) a cyclosporin, wherein the liposomes comprise umilamellar vesicles having a diameter of less than 0.2 .mu.m.
Therapeutic liposomes consisting essentially of (i) a phosphatidylcholine having lipid portions composed of straight 16 or 18 carbon fatty acid chains, (ii) a negatively charged lipid selected from the group consisting of dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dilaurylphosphatidylglycerol and dimyristoylphosphatidic acid, and (iii) a cyclosporin, wherein the liposomes comprise unilamellar vesicles having a diameter of less than 0.2 .mu.m.
Therapeutic liposomes consisting essentially of (i) a phosphatidylcholine having lipid portions composed of straight 16 or 18 carbon fatty acid chains, (ii) a negatively charged lipid selected from the group consisting of dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, dilaurylphosphatidylglycerol and dimyristoylphosphatidic acid, (iii) cholesterol, and (iv) a cyclosporin, wherein the liposomes comprise unilamellar vesicles having a diameter of less than 0.2 .mu.m.
Dependencies are inferred from the claim text.